U Testa1, R Riccioni, D Diverio
1Department of Hematology and Oncology, Istituto Superiore di Sanità, Viale Regina Elena 299, Rome, Italy. u.testa@iss.it
Interleukin-3 receptor (IL-3R) abnormalities are common in acute myeloid leukemias (AMLs), driving leukemic cell growth. Targeting IL-3R offers a promising strategy for novel AML therapies.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: